Alizapride Hydrochloride - CAS 59338-87-3
Not Intended for Therapeutic Use. For research use only.
Product Name:
Alizapride Hydrochloride
Catalog Number:
CAS Number:
Alizapride is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.
Molecular Weight:
Molecular Formula:
Dopamine receptor
Catalog Number Size Price Stock Quantity
B0084-095175 200 mg $249 In stock
Bulk Inquiry
Chemical Structure
CAS 59338-87-3 Alizapride Hydrochloride

Reference Reading

1.Use of anti-emetics after intragastric balloon placement: experience with three different drug treatments.
Van Hee R1, Van Wiemeersch S, Lasters B, Weyler J. Obes Surg. 2003 Dec;13(6):932-7.
BACKGROUND: Tropisetron treatment was compared with alizapride treatment. The secondary aim was to assess whether droperidol supplement would still improve the therapeutic outcome of tropisetron.
2.Study of the prophylactic effect of droperidol, alizapride, propofol and promethazine on spinal morphine-induced pruritus.
Horta ML1, Morejon LC, da Cruz AW, Dos Santos GR, Welling LC, Terhorst L, Costa RC, Alam RU. Br J Anaesth. 2006 Jun;96(6):796-800. Epub 2006 Apr 5.
BACKGROUND: We have compared the use of alizapride, propofol, droperidol and promethazine for the prevention of spinal morphine-induced pruritus.
3.In vitro metabolic fate of alizapride: evidence for the formation of reactive metabolites based on liquid chromatography-tandem mass spectrometry.
Aprile S1, Del Grosso E, Grosa G. J Mass Spectrom. 2012 Jun;47(6):737-50. doi: 10.1002/jms.3011.
The study of the formation of reactive metabolites during drug metabolism is one of the major areas of research in drug development since the link between reactive metabolites and drug adverse effects was well recognized. In particular, it has been shown that acrolein, a reactive carbonyl species sharing carbonylating and alkylating properties, binds covalently to nucleophilic sites in proteins, causing cellular damage. Alizapride, (±)-6-methoxy-N-{[1-(prop-2-en-1-yl)-pyrrolidin-2-yl]methyl}-1H-benzotriazole-5-carboxamide, is a N-allyl containing dopamine antagonist with antiemetic properties for which no data concerning its metabolic fate are so far reported. The study of the in vitro metabolism of alizapride showed the formation of acrolein during the oxidative N-deallylation. Moreover, the formation of an epoxide metabolite has been also described suggesting its role as a putative structural alert. The reactivity of the acrolein and the epoxide generated in alizapride metabolism was demonstrated by the formation of the corresponding adducts with nucleophilic thiols.